Prosigna® Test: A New Era of Personalized Breast Cancer Care (2026)

Written by: Steve Fong
Medically Reviewed by: One Day MD Editorial Team

Cancer treatment is no longer a one-size-fits-all approach. Advances in precision medicine now allow doctors to better understand the unique biology of each patient's cancer and make more informed treatment decisions. One important innovation in this field is the Prosigna® Test.

What Is the Prosigna Test?

The Prosigna Test is a genomic assay designed for certain types of early-stage breast cancer. By analyzing the expression of 50 genes within a tumor (known as the PAM50 gene signature), the test helps estimate the risk of cancer recurrence and provides valuable information about the tumor's molecular subtype.

Unlike traditional pathology tests that focus primarily on how cancer cells appear under a microscope, the Prosigna Test examines the tumor's underlying genetic activity, offering a deeper understanding of its biological behavior.

Why Is the Prosigna Test Important?

Traditionally, breast cancer treatment decisions have been based on factors such as tumor size, grade, hormone receptor status, and lymph node involvement. While these factors remain essential, they do not always provide a complete picture of an individual's risk of recurrence.

The Prosigna Test offers additional insights by:

✅ Estimating the likelihood of breast cancer recurrence over time

✅ Identifying the tumor's intrinsic molecular subtype

✅ Supporting more personalized treatment planning

✅ Helping guide decisions regarding the potential benefit of additional therapies

By providing a more individualized risk assessment, the test can help clinicians tailor treatment recommendations to each patient's unique situation.

Benefits for Patients

Having more precise information about a tumor can help patients and healthcare providers make better-informed treatment decisions. The Prosigna Test may help reduce uncertainty and facilitate meaningful discussions about the risks and benefits of different treatment options.

For some patients, genomic testing can provide reassurance that their treatment plan is appropriate for their level of risk. For others, it may identify a need for closer monitoring or additional therapy.

The Future of Precision Oncology

Genomic testing represents a significant advancement in modern cancer care. Tools such as the Prosigna Test are helping move oncology toward a more personalized approach, where treatment recommendations are guided not only by what a tumor looks like under a microscope but also by its unique genetic signature.

As cancer research continues to evolve, innovative diagnostic technologies are empowering both physicians and patients with more accurate information, supporting personalized, evidence-based treatment decisions and improving the quality of cancer care.

Knowledge is power. Early detection, accurate diagnosis, and personalized treatment planning remain essential components in the fight against breast cancer.